RenovoRx Announces The U.S. Patent And Trademark Office Issuance Of Two Patents
LOS ALTOS, Calif., Oct. 13, 2016 /PRNewswire/ -- RenovoRx, a leading developer of innovative solutions for targeted therapy today announced that the company has received two new device patents, Devices Methods and Kits for Delivery of Therapeutic Materials to a Target Artery (U.S. Patent No. 9,457,171 and U.S. Patent No. 9,463,304) for its RenovoCath delivery catheter. The RenovoCath is indicated for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vasculature system.
The issuance of these two patents is a major milestone for RenovoRx and will strengthen the company's technology portfolio. In 2014, RenovoRx received a method patent entitled "Devices, Methods and Kits for Delivery of Therapeutic Material to the Pancreas (U.S. patent no. 8,821,476).
"The patents come at a time when the company is gaining traction. RenovoRx is seeing early adoption of its catheter in select centers across the US, and the RenovoCath has delivered promising results in procedures tackling difficult to treat diseases, including pelvic vein congestion, adenocarcinoma of the pancreas, and liver cancer," says Shaun Bagai, the company's CEO.
According to Dr. David Madoff (Professor of Radiology, Vice Chairman of Academic Affairs, New York Presbyterian Hospital Weill Cornell Medical College), the RenovoCath allowed him to successfully treat a patient he might otherwise not have been able to help:
"This case was one where the numerous feeding vessels were so small that performing particle embolization was difficult (urothelial carcinoma metastases not highly vascular HCC). I performed conventional TACE, and the results by imaging were great (follow-up results are not yet known). This would have been impossible without this catheter."
About RenovoRx
RenovoRx (www.renovorx.com) is developing innovative solutions for the isolation of blood flow and delivery of fluids, including diagnostic materials and therapeutic agents, to selected sites in the peripheral vascular system. The ability to deliver these materials at high concentration to specific vasculature, safely and without perfusion overlap to other regions, is a central paradigm of the company's technology. RenovoRx is based in Silicon Valley, California, and its top financial backers include Astia Angels, Golden Seeds, Sand Hill Angels, The Angels' Forum, The Halo Fund III, L.P., Plug and Play, and Rising Tide Fund/Portfolia.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/renovorx-announces-the-us-patent-and-trademark-office-issuance-of-two-patents-300344213.html
SOURCE RenovoRx
